RT Journal Article
SR Electronic
T1 Polygenic score informed by genome-wide association studies of multiple ancestries and related traits improves risk prediction for coronary artery disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.03.03.23286649
DO 10.1101/2023.03.03.23286649
A1 Patel, Aniruddh P.
A1 Wang, Minxian
A1 Ruan, Yunfeng
A1 Koyama, Satoshi
A1 Clarke, Shoa L.
A1 Yang, Xiong
A1 Tcheandjieu, Catherine
A1 Agrawal, Saaket
A1 Fahed, Akl C.
A1 Ellinor, Patrick T.
A1 ,
A1 ,
A1 Tsao, Phillip S.
A1 Sun, Yan V.
A1 Cho, Kelly
A1 Wilson, Peter W. F.
A1 Assimes, Themistocles L.
A1 van Heel, David A.
A1 Butterworth, Adam S.
A1 Aragam, Krishna G.
A1 Natarajan, Pradeep
A1 Khera, Amit V.
YR 2023
UL http://medrxiv.org/content/early/2023/03/05/2023.03.03.23286649.abstract
AB Accurate stratification of coronary artery disease (CAD) risk remains a critical need. A new polygenic score (GPSMult) incorporates CAD genome-wide association data across five ancestries (>269,000 cases, >1,178,000 controls) with genetic association data for ten CAD risk factors. GPSMult associates with an OR/SD 2.14, (95%CI:2.10-2.19,P<0.001) for prevalent CAD and HR/SD 1.73 (95%CI 1.70-1.76,P<0.001) for incident CAD. When compared with the previously published GPS2018 in external datasets, GPSMult demonstrated 73%, 46%, and 113% increase in effect size for individuals of African, European, and South Asian ancestry, respectively, and significantly outperformed recently published CAD polygenic scores. GPSMult identifies individuals with CAD risk extremes, including the top 3% of the population at equivalent risk for a new CAD event as those with prior CAD having a second event. Integrating GPSMult with the Pooled Cohort Equations results in 7.0% [95%CI:5.9%-8.2%,P<0.001] net reclassification improvement at the 7.5% threshold. Large-scale integration genetic association data for CAD and related traits from diverse populations meaningfully improves polygenic risk prediction.Competing Interest StatementS.A. has served as a scientific advisor to Third Rock Ventures. A.C.F. is a co-founder of Goodpath and reports a grant from Abbott Vascular. P.T.E. receives sponsored research support from Bayer AG and IBM Research; he has also served on advisory boards or consulted for Bayer AG, MyoKardia and Novartis. P.N. reports investigator-initiated grants from Amgen, Apple, AstraZeneca, Boston Scientific, and Novartis, personal fees from Apple, AstraZeneca, Blackstone Life Sciences, Foresite Labs, Novartis, Roche / Genentech, is a co-founder of TenSixteen Bio, is a scientific advisory board member of Esperion Therapeutics, geneXwell, and TenSixteen Bio, and spousal employment at Vertex Pharmaceuticals, all unrelated to the present work. A.V.K. is an employee of Verve Therapeutics; has served as a scientific advisor to Amgen, Novartis, Silence Therapeutics, Korro Bio, Veritas International, Color Health, Third Rock Ventures, Illumina, Ambry, and Foresite Labs; holds equity in Verve Therapeutics, Color Health, and Foresite Labs; and is listed as a co-inventor on patent applications related to assessment and mitigation of risk associated with perturbations in body fat distribution.Funding StatementThis work was supported by the KL2/Catalyst Medical Research Investigator Training award from Harvard Catalyst (to A.P.P. and K.G.A.); the Sarnoff Cardiovascular Research Foundation Fellowship (to S.A.); grants 1K08HL153937 (to K.G.A.),1K08HL161448 (to A.C.F.), R01HL1427 (to P.N.), R01HL148565 (to P.N.), R01HL148050 (to P.N.), 1RO1HL092577 (to P.T.E.), 1R01HL157635 (to P.T.E.), and 1R01HL157635 (to P.T.E.) from the National Heart, Lung, and Blood Institute; grant 862032 (to K.A.) and grants 18SFRN34110082 (to P.T.E.), 17IFUNP3384001 (to .G.A.) from the American Heart Association; grant MAESTRIA 965286 from the European Union (to P.T.E.); grants 1K08HG010155 and 1U01HG011719 from the National Human Genome Research Institute (to A.P.P., P.N., and A.V.K.); a Hassenfeld Scholar Award from Massachusetts General Hospital (to P.N. and A.V.K.); a Merkin Institute Fellowship from the Broad Institute of MIT and Harvard (to A.V.K.). This research has been conducted using the UK Biobank Resource, and we thank the volunteers participating. This research is based on data from the Million Veteran Program, Office of Research and Development, Veterans Health Administration, and was supported by Veterans Administration awards I01-01BX003362, I01-BX004821 (P.S.T), I01-BX003340 (P.W.F.W) and VA HSR RES 13-457 (VA Informatics and Computing Infrastructure). The content of this manuscript does not represent the views of the Department of Veterans Affairs or the United States Government. Genes & Health is/has recently been core-funded by Wellcome (WT102627, WT210561), the Medical Research Council (UK) (M009017, MR/X009777/1, MR/X009920/1), Higher Education Funding Council for England Catalyst, Barts Charity (845/1796), Health Data Research UK (for London substantive site), and research delivery support from the NHS National Institute for Health Research Clinical Research Network (North Thames). Genes & Health is/has recently been funded by Alnylam Pharmaceuticals, Genomics PLC; and a Life Sciences Industry Consortium of Astra Zeneca PLC, Bristol-Myers Squibb Company, GlaxoSmithKline Research and Development Limited, Maze Therapeutics Inc, Merck Sharp & Dohme LLC, Novo Nordisk A/S, Pfizer Inc, Takeda Development Centre Americas Inc. We thank Social Action for Health, Centre of The Cell, members of our Community Advisory Group, and staff who have recruited and collected data from volunteers. We thank the NIHR National Biosample Centre (UK Biocentre), the Social Genetic & Developmental Psychiatry Centre (King's College London), Wellcome Sanger Institute, and Broad Institute for sample processing, genotyping, sequencing and variant annotation. We thank: Barts Health NHS Trust, NHS Clinical Commissioning Groups (City and Hackney, Waltham Forest, Tower Hamlets, Newham, Redbridge, Havering, Barking and Dagenham), East London NHS Foundation Trust, Bradford Teaching Hospitals NHS Foundation Trust, Public Health England (especially David Wyllie), Discovery Data Service/Endeavour Health Charitable Trust (especially David Stables), NHS Digital - for GDPR-compliant data sharing backed by individual written informed consent. Most of all we thank all of the volunteers participating in Genes & Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research and secondary data use was approved by the Mass General Brigham institutional review board.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data are made available from the UK Biobank to researchers from universities and other institutions with genuine research inquiries following institutional review board and UK Biobank approval. This research was conducted using the UK Biobank resource under Application Number 7089 and secondary data use was approved by the Mass General Brigham institutional review board. Summary statistics from Biobank Japan are available at http://jenger.riken.jp/en/result. Summary statistics for the Coronary ARtery DIsease Genome wide Replication and Meta-analysis plus The Coronary Artery Disease Genetics consortium (CARDIoGRAMplusC4D) study are available at http://www.cardiogramplusc4d.org. Summary statistics from FinnGen are available at https://www.finngen.fi/en/access_results. Summary statistics from Genes & Health are available at https://www.genesandhealth.org/research/scientific-data-downloads. Summary statistics from the Million Veteran Program are available in dbGaP (accession number phs001672). The full GPSMult weights will be available in the Polygenic Score Catalog.